Clinical Trial Update: Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 trial of Bendamustine plus Rituximab in adults aged 65 and older with Chronic Lymphocytic Leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituxan (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: University of Kentucky | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: WITHDRAWN